Journal of the American College of Surgeons
Volume 208, Issue 2 , Pages 202-209, February 2009

Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer

Abstract presented at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.

  • Monika K. Krzyzanowska, MD, MPH

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorrespondence address: Monika K Krzyzanowska, MD, MPH, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Ste 5-206, Toronto, Ontario M5G 2M9, Canada
  • ,
  • Meredith M. Regan, ScD

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
  • ,
  • Mark Powell, MA, MEd

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
  • ,
  • Craig C. Earle, MD, MS

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
  • ,
  • Jane C. Weeks, MD, MSc

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA

Received 5 June 2008; received in revised form 6 October 2008; accepted 6 October 2008. published online 18 December 2008.

Background

To study surgeons' versus oncologists' preferences for adjuvant chemotherapy for elderly patients with stage III colon cancer, as population studies indicate that such patients are less likely to receive treatment.

Study Design

A vignette-based survey was mailed to a nationally representative sample of 1,000 general surgeons and 1,000 oncologists in the United States. Patient age, comorbidity level, and preference were varied across eight vignettes. Physician preference for referral (surgeons) or treatment (oncologists) was measured using a 7-point Likert scale. Mixed-effects linear regression was used to evaluate the results.

Results

One thousand twenty-nine surveys were returned (response rate of 54%). Among surgeons, increasing age and more severe comorbidity resulted in lower likelihood of referral to oncologist: mean difference in preference scores for vignettes describing a 61-year-old versus an 83-year-old patient (adjusted for comorbidity) was 0.77 (p < 0.0001); mean difference in scores between vignettes describing a patient with none versus severe comorbidity, adjusted for age, was 1.94 (p < 0.0001). Among oncologists, patient age and comorbidity interacted significantly (p < 0.0001) to affect oncologists' preferences: both increasing age and more severe comorbidity resulted in decreased preference for recommending adjuvant chemotherapy, but oncologists were more heavily influenced by comorbidity at younger patient age. Patient preference against therapy also affected physicians' recommendations (p < 0.0001), but the magnitude of effect was small relative to age and comorbidity.

Conclusion

Patient age and comorbidity level influence both types of physicians' preferences about adjuvant chemotherapy for colon cancer and might explain some of the patterns of care seen for this disease in population-based studies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosure Information: Nothing to disclose.

 Supported by an American Society of Clinical Oncology Young Investigator Award and a Fellowship Award from the National Cancer Institute of Canada. Neither sponsor had a role in the design or interpretation of this study.

PII: S1072-7515(08)01530-5

doi:10.1016/j.jamcollsurg.2008.10.016

Journal of the American College of Surgeons
Volume 208, Issue 2 , Pages 202-209, February 2009